- Braveheart Bio's Hengrui-licensed cardiac drug scores second clinical winBraveheart Bio said Monday that the heart muscle therapy it licensed from China’s Jiangsu Hengrui Pharmaceuticals has succeeded in a mid-stage trial for the same condition in which Cytokinetics rec…Endpoints · 2mo ago↗ source
- Biotech layoffs are easing, but is the worst over?<figure><div><img src="https://imgproxy.divecdn.com/TL3Qf7mHRlVjEhCJI35ocLIfavZ0TUEHiNIVNf4xjm8/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9TY3JlZW5zaG90XzIwMjYtMDUtMDdfYXRfM…BioPharma Dive · 2mo ago↗ source
- European regulators greenlight Fractyl Health's clinical test of GLP-1 gene therapyDrug developers are racing to make gene therapies that could replace chronic GLP-1 injections and pills with a one-and-done treatment. Now, a company based just outside of Boston is poised to becom…